ArticleDiscover oncology2024

Efficacy and safety of tislelizumab plus bacillus-calmette guérin with or without chemotherapy as a bladder-sparing treatment for high-risk non-muscle-invasive bladder urothelial cancer: a real-world study.

Peng Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.